JP2016190870A5 - - Google Patents

Download PDF

Info

Publication number
JP2016190870A5
JP2016190870A5 JP2016152831A JP2016152831A JP2016190870A5 JP 2016190870 A5 JP2016190870 A5 JP 2016190870A5 JP 2016152831 A JP2016152831 A JP 2016152831A JP 2016152831 A JP2016152831 A JP 2016152831A JP 2016190870 A5 JP2016190870 A5 JP 2016190870A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016152831A
Other versions
JP2016190870A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016190870A publication Critical patent/JP2016190870A/ja
Publication of JP2016190870A5 publication Critical patent/JP2016190870A5/ja
Withdrawn legal-status Critical Current

Links

JP2016152831A 2008-08-15 2016-08-03 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤 Withdrawn JP2016190870A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8942208P 2008-08-15 2008-08-15
US61/089,422 2008-08-15
US27333209P 2009-08-03 2009-08-03
US61/273,332 2009-08-03
US23172509P 2009-08-06 2009-08-06
US61/231,725 2009-08-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014092883A Division JP6034327B2 (ja) 2008-08-15 2014-04-28 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2018070899A Division JP2018104469A (ja) 2008-08-15 2018-04-02 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2018070898A Division JP6473532B2 (ja) 2008-08-15 2018-04-02 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤

Publications (2)

Publication Number Publication Date
JP2016190870A JP2016190870A (ja) 2016-11-10
JP2016190870A5 true JP2016190870A5 (ja) 2017-03-30

Family

ID=41666602

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2011523004A Active JP5770629B2 (ja) 2008-08-15 2009-08-14 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2014092883A Active JP6034327B2 (ja) 2008-08-15 2014-04-28 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2016152831A Withdrawn JP2016190870A (ja) 2008-08-15 2016-08-03 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2018070898A Active JP6473532B2 (ja) 2008-08-15 2018-04-02 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2018070899A Withdrawn JP2018104469A (ja) 2008-08-15 2018-04-02 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2019126707A Withdrawn JP2019163340A (ja) 2008-08-15 2019-07-08 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2021018125A Withdrawn JP2021073297A (ja) 2008-08-15 2021-02-08 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2022111842A Withdrawn JP2022132383A (ja) 2008-08-15 2022-07-12 経口投与に好適なgc-c受容体アゴニストポリペプチドの安定な固体製剤
JP2023209257A Withdrawn JP2024015361A (ja) 2008-08-15 2023-12-12 経口投与に好適なgc-c受容体アゴニストポリペプチドの安定な固体製剤
JP2025080475A Pending JP2025109853A (ja) 2008-08-15 2025-05-13 経口投与に好適なgc-c受容体アゴニストポリペプチドの安定な固体製剤

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2011523004A Active JP5770629B2 (ja) 2008-08-15 2009-08-14 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2014092883A Active JP6034327B2 (ja) 2008-08-15 2014-04-28 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2018070898A Active JP6473532B2 (ja) 2008-08-15 2018-04-02 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2018070899A Withdrawn JP2018104469A (ja) 2008-08-15 2018-04-02 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2019126707A Withdrawn JP2019163340A (ja) 2008-08-15 2019-07-08 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2021018125A Withdrawn JP2021073297A (ja) 2008-08-15 2021-02-08 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2022111842A Withdrawn JP2022132383A (ja) 2008-08-15 2022-07-12 経口投与に好適なgc-c受容体アゴニストポリペプチドの安定な固体製剤
JP2023209257A Withdrawn JP2024015361A (ja) 2008-08-15 2023-12-12 経口投与に好適なgc-c受容体アゴニストポリペプチドの安定な固体製剤
JP2025080475A Pending JP2025109853A (ja) 2008-08-15 2025-05-13 経口投与に好適なgc-c受容体アゴニストポリペプチドの安定な固体製剤

Country Status (32)

Country Link
US (7) US8802628B2 (ja)
EP (2) EP3701962A1 (ja)
JP (10) JP5770629B2 (ja)
KR (11) KR20170138580A (ja)
CN (5) CN102186490B (ja)
AU (1) AU2009282446B2 (ja)
BR (1) BRPI0917807A2 (ja)
CA (1) CA2732892C (ja)
CL (1) CL2011000314A1 (ja)
CO (1) CO6351746A2 (ja)
CY (1) CY1122801T1 (ja)
DK (1) DK2328601T3 (ja)
EA (1) EA201170337A1 (ja)
ES (1) ES2785980T3 (ja)
GE (1) GEP20156209B (ja)
HK (1) HK1219062A1 (ja)
HR (1) HRP20200512T2 (ja)
HU (1) HUE049023T2 (ja)
IL (1) IL211028A (ja)
LT (1) LT2328601T (ja)
MX (4) MX2011001620A (ja)
NZ (1) NZ591713A (ja)
PE (2) PE20110543A1 (ja)
PH (1) PH12015501579B1 (ja)
PL (1) PL2328601T3 (ja)
PT (1) PT2328601T (ja)
RS (1) RS60101B1 (ja)
SG (1) SG193801A1 (ja)
SI (1) SI2328601T1 (ja)
SM (1) SMT202000179T1 (ja)
WO (1) WO2010019266A2 (ja)
ZA (1) ZA201101523B (ja)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170138580A (ko) 2008-08-15 2017-12-15 아이언우드 파마슈티컬스, 인코포레이티드 경구 투여를 위한 리나클로타이드-함유 제형
JP5964589B2 (ja) 2008-12-03 2016-08-03 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼcアゴニストの製剤およびその使用方法
CA2770077A1 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
RU2012109415A (ru) * 2009-08-13 2013-09-20 Айронвуд Фармасьютикалз, Инк. Способ модуляции фармакодинамического эффекта перорально вводимых агонистов рецептора гуанилатциклазы
US20130059797A1 (en) * 2009-11-03 2013-03-07 Forest Laboratories Holdings Limited Linaclotide for the Treatment of Chronic Constipation
PH12012500916B1 (en) * 2009-11-09 2018-03-23 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
KR20120103689A (ko) 2009-12-07 2012-09-19 아이언우드 파마슈티컬스, 인코포레이티드 위장 장애의 치료
UA108636C2 (xx) * 2010-02-17 2015-05-25 Пептид
LT2603232T (lt) * 2010-08-11 2020-01-27 Ironwood Pharmaceuticals, Inc. Stabilios linaklotido vaisto formos
JP2013540732A (ja) * 2010-09-11 2013-11-07 アイロンウッド ファーマシューティカルズ, インコーポレイテッド 便秘型過敏性腸症候群の処置
CA2810243C (en) 2010-09-15 2021-04-20 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
US9616097B2 (en) * 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2835624A1 (en) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9303066B2 (en) 2011-05-11 2016-04-05 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012170804A1 (en) * 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012170766A1 (en) 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
ES2614864T3 (es) 2011-08-17 2017-06-02 Ironwood Pharmaceuticals, Inc. Tratamientos para trastornos gastrointestinales
US20140242158A1 (en) * 2011-09-30 2014-08-28 Astellas Pharma, Inc. Granular Pharmaceutical Composition
WO2014088623A1 (en) * 2012-07-12 2014-06-12 Forest Laboratories Holdings Limited Linaclotide compositions
WO2014118180A1 (en) * 2013-01-30 2014-08-07 Sandoz Ag Crystalline form of linaclotide
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス,インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
UA119335C2 (uk) 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
US10272131B2 (en) * 2014-08-11 2019-04-30 Sun Pharmaceutical Industries Ltd. Linaclotide stable composition
EP3006045B3 (en) * 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
CN104569245A (zh) * 2014-12-08 2015-04-29 江苏泰洁检测技术有限公司 一种工作场所脂肪族胺类中环己胺浓度测定方法
US20180008547A1 (en) * 2015-02-02 2018-01-11 Aurobindo Pharma Ltd Stable Compositions comprising Linaclotide
WO2016197042A1 (en) * 2015-06-05 2016-12-08 Ironwood Pharmaceuticals, Inc. Modified or targeted release formulations of linaclotide
JP2018529749A (ja) 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
WO2018119191A1 (en) 2016-12-21 2018-06-28 Ironwood Pharmaceuticals Inc. Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide
CN107669700A (zh) * 2017-09-14 2018-02-09 湖南晓林生物科技发展有限公司 一种治疗溃疡性结肠炎的药物及其制备方法
WO2020012243A2 (en) 2018-07-09 2020-01-16 Abbott Laboratories Gmbh Pharmaceutical composition containing a peptide
CN114340631A (zh) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 用于降低患者的血清磷酸盐的组合
CN112121021B (zh) * 2019-06-24 2022-03-25 深圳翰宇药业股份有限公司 一种含利那洛肽的药物组合物及其制备方法
JP2021104941A (ja) * 2019-12-26 2021-07-26 ニプロ株式会社 薬物高含有量錠剤及びその製造方法
US20230226143A1 (en) * 2020-06-30 2023-07-20 Ocvirk, Soren Pharmaceutical composition comprising a combination of a guanylate cyclase c (gucy2c) agonist and a short-chain fatty acid or prodrug thereof
CN113616616A (zh) * 2021-09-07 2021-11-09 四川国为制药有限公司 一种利那洛肽胶囊制剂及其制备方法
US20230106943A1 (en) * 2021-09-17 2023-04-06 Peptilogics, Inc. Engineered antimicrobial peptides and usage thereof
CN114632141B (zh) * 2022-04-19 2023-08-01 苏州中化药品工业有限公司 一种含利那洛肽的药物组合物、胶囊制剂及其制备方法
CN116672309A (zh) * 2023-07-26 2023-09-01 北京普诺旺康医药科技有限公司 干混悬药物组合物

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH658973A5 (fr) 1983-12-29 1986-12-31 Nestle Sa Produit aromatisant.
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JPS649938A (en) 1987-06-30 1989-01-13 Agency Ind Science Techn Oral ingestive composition
CA2028848A1 (en) 1989-04-11 1990-10-12 Tapan Audhya Lyophilized peptide formulations
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
US5221495A (en) 1990-04-13 1993-06-22 Colgate-Palmolive Company Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions
US5451410A (en) 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
NZ333580A (en) 1996-07-03 2000-06-23 Alza Corp Non-Aqueous protic peptide formulations, preferably LHRH
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5916582A (en) 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
US20020151502A1 (en) * 1997-10-09 2002-10-17 Albert Sattin Tri-peptides for neurological and neurobehavior applications
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6087478A (en) 1998-01-23 2000-07-11 The Rockefeller University Crystal of the N-terminal domain of a STAT protein and methods of use thereof
AU5026599A (en) 1998-07-23 2000-02-14 Novo Nordisk A/S A wet granulation method for preparing a stable pharmaceutical formulation
JP2002524358A (ja) * 1998-09-04 2002-08-06 ガプラスト ゲーエムベーハー 容 器
BR9916871A (pt) 1998-11-27 2001-08-21 Kanji Takada Formulação oral para fornecimento de drogas gastrointestinais
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
KR20080015888A (ko) 2000-06-28 2008-02-20 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
FR2811884B1 (fr) 2000-07-21 2003-01-31 Oreal Utilisation en cosmetique de betainates d'amidon et composition les comprenant associes a au moins un agent benefique pour les matieres keratiniques
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2002026248A1 (en) 2000-09-29 2002-04-04 Cognetix, Inc. Stable peptide formulations
ES2281458T3 (es) 2000-12-21 2007-10-01 Nektar Therapeutics Composiciones de polvo estables en almacenamiento del receptor de interleucina 4.
JP2004521123A (ja) 2001-02-02 2004-07-15 ファルマシア・コーポレーション 腸癌阻害のためのウログアニリンおよびシクロオキシゲナーゼ−2阻害薬の組合わせ
GB0104371D0 (en) 2001-02-22 2001-04-11 Clariant Int Ltd Color improving stabilizing compositions comprising leucine
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
ES2622468T3 (es) 2001-03-29 2017-07-06 Synergy Pharmaceuticals, Inc. Agonistas del receptor de guanilato ciclasa para el tratamiento de inflamación tisular y carcinogénesis
WO2003014304A2 (en) 2001-08-09 2003-02-20 Doctor's Signature Sales And Marketing International Corp. [(Dba)] Life Force International Protonic formulation
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
PL370656A1 (en) * 2001-12-21 2005-05-30 Novo Nordisk A/S Liquid composition of modified factor vii polypeptides
JP2003201256A (ja) 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
DE10261126A1 (de) * 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
CN1726012A (zh) 2002-12-11 2006-01-25 辉瑞产品公司 活性物质在高脂肪环境中的控制释放
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
SI1594517T1 (sl) 2003-01-28 2007-10-31 Microbia Inc Sestavki za zdravljenje gastrointestinalnih motenj
DK1638586T3 (da) 2003-05-14 2008-06-23 Indus Biotech Pvt Ltd Synergistisk sammensætning til behandling af diabetes mellitus
EP1641486B1 (en) * 2003-06-10 2012-04-18 LG Life Sciences Ltd. Stable, aqueous solution of human erythropoietin, not containing serum albumin
PT1644021E (pt) 2003-06-13 2013-01-30 Ironwood Pharmaceuticals Inc Métodos e composições para o tratamento de distúrbios gastrointestinais
US7494979B2 (en) 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
KR100560697B1 (ko) 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
DE102004011663B4 (de) 2004-03-10 2006-04-27 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
JP4744533B2 (ja) 2004-12-30 2011-08-10 ドゥビエル カンパニー リミテッド 噴霧乾燥高分子型コレクチン属タンパク質及びその製造方法
EP1940441A4 (en) 2005-08-19 2010-01-27 Ironwood Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL DISORDERS
WO2007044375A2 (en) 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
JP2009527504A (ja) * 2006-02-23 2009-07-30 イオメディックス スリープ インターナショナル エスアールエル 良質な睡眠の誘導および維持のための組成物および方法
CA2652677A1 (en) 2006-02-24 2007-09-07 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ITMI20060629A1 (it) 2006-03-31 2007-10-01 Daniele Giovannone Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
EP2046363A1 (en) 2006-07-10 2009-04-15 Österreichische Akademie der Wissenschaften Antimicrobial peptides
JP5048773B2 (ja) 2006-08-09 2012-10-17 インターシア セラピューティクス,インコーポレイティド 浸透圧式デリバリーシステム及びピストンアセンブリー
CN101557827A (zh) 2006-08-31 2009-10-14 诺瓦提斯公司 用于口服递送的包含hgh的药物组合物
CA2673260A1 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
US8779090B2 (en) 2007-02-26 2014-07-15 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
KR20170138580A (ko) 2008-08-15 2017-12-15 아이언우드 파마슈티컬스, 인코포레이티드 경구 투여를 위한 리나클로타이드-함유 제형
US20120009225A1 (en) * 2008-09-04 2012-01-12 Ironwood Pharmaceuticals, Inc. Stable Solid Formulation of Therapeutic Polypeptides Suitable for Oral Administration
US20120039949A1 (en) * 2008-09-04 2012-02-16 Ironwood Pharmaceuticals, Inc. Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration
JP5964589B2 (ja) 2008-12-03 2016-08-03 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼcアゴニストの製剤およびその使用方法
US20130012454A1 (en) * 2009-07-06 2013-01-10 Ironwood Pharmaceuticals, Inc. Orally Disintegrating Compositions of Linaclotide
CA2770077A1 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
CA2770334A1 (en) 2009-08-12 2011-02-17 Forest Laboratories Holdings Limited Orally disintegrating compositions of linaclotide

Similar Documents

Publication Publication Date Title
JP2016190870A5 (ja)
CN303536567S (ja)
CN303536594S (ja)
CN303639277S (ja)
CN303633867S (ja)
CN303617185S (ja)
CN303593737S (ja)
CN303576756S (ja)
CN303541589S (ja)
CN303538760S (ja)
CN303538755S (ja)
CN303538751S (ja)
CN303538743S (ja)
CN303538699S (ja)
CN303538690S (ja)
CN303538638S (ja)
CN303538553S (ja)
CN303538480S (ja)
CN303538069S (ja)
CN303538066S (ja)
CN303538000S (ja)
CN303537999S (ja)
CN303537912S (ja)
CN303537759S (ja)
CN303537608S (ja)